Autoantibody profiling to follow evolution of lupus syndromes

Nancy Olsen, Quan Zhen Li, Jiexia Quan, Ling Wang, Azza Mutwally, David R. Karp

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Introduction: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness.Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined.Results: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10 -7). Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.

Original languageEnglish (US)
Article numberR174
JournalArthritis Research and Therapy
Volume14
Issue number4
DOIs
StatePublished - Jul 27 2012

Fingerprint

Autoantibodies
Immunoglobulin G
Systemic Lupus Erythematosus
Immunoglobulin M
Demography
beta 2-Microglobulin
Hemocyanin
Antibody Specificity
Triage
Autoantigens
Proliferating Cell Nuclear Antigen
Routine Diagnostic Tests
Cytosol
Disease Progression
Physicians
Kidney
Liver

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Olsen, N., Li, Q. Z., Quan, J., Wang, L., Mutwally, A., & Karp, D. R. (2012). Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Research and Therapy, 14(4), [R174]. https://doi.org/10.1186/ar3927
Olsen, Nancy ; Li, Quan Zhen ; Quan, Jiexia ; Wang, Ling ; Mutwally, Azza ; Karp, David R. / Autoantibody profiling to follow evolution of lupus syndromes. In: Arthritis Research and Therapy. 2012 ; Vol. 14, No. 4.
@article{6883f5eed0e94b10bdede0dc92d8053c,
title = "Autoantibody profiling to follow evolution of lupus syndromes",
abstract = "Introduction: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness.Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined.Results: 3 of the 22 patients (14{\%}) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10 -7). Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.",
author = "Nancy Olsen and Li, {Quan Zhen} and Jiexia Quan and Ling Wang and Azza Mutwally and Karp, {David R.}",
year = "2012",
month = "7",
day = "27",
doi = "10.1186/ar3927",
language = "English (US)",
volume = "14",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "4",

}

Autoantibody profiling to follow evolution of lupus syndromes. / Olsen, Nancy; Li, Quan Zhen; Quan, Jiexia; Wang, Ling; Mutwally, Azza; Karp, David R.

In: Arthritis Research and Therapy, Vol. 14, No. 4, R174, 27.07.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Autoantibody profiling to follow evolution of lupus syndromes

AU - Olsen, Nancy

AU - Li, Quan Zhen

AU - Quan, Jiexia

AU - Wang, Ling

AU - Mutwally, Azza

AU - Karp, David R.

PY - 2012/7/27

Y1 - 2012/7/27

N2 - Introduction: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness.Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined.Results: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10 -7). Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.

AB - Introduction: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness.Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined.Results: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10 -7). Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.

UR - http://www.scopus.com/inward/record.url?scp=84864198971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864198971&partnerID=8YFLogxK

U2 - 10.1186/ar3927

DO - 10.1186/ar3927

M3 - Article

VL - 14

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 4

M1 - R174

ER -